20 articles
Aalto University researchers found that gentle near-infrared heat can trigger eye cells' natural repair systems, potentially stopping dry AMD early.
Scientists found dragonflies see deep red light like humans do, opening doors for new light-based therapies that work inside the body.
Rubedo's RLS-1496 reduced actinic keratosis lesions by 46% in four weeks with minimal side effects, targeting aging cells behind the damage.
Rubedo's RLS-1496 cream slashed actinic keratosis lesions nearly in half at 4 weeks with no serious side effects in early trial data.
Topical therapy RLS-1496 met primary endpoints in Phase 1 trial with no serious adverse events in psoriasis patients.
PulseSight's iron-regulating gene therapy slowed geographic atrophy growth in a first-in-human trial, with Phase 2 planned for 2026.
Boston study reveals artificial light at night triggers brain stress and artery inflammation, raising cardiovascular disease risk significantly.
QT-019B targets two cancer markers at once using off-the-shelf engineered T cells, now holding every major FDA expedited development status.
Rubedo's RLS-1496 demonstrates early clinical signals in removing senescent cells through GPX4 modulation in human skin tissue.
Definium's single-dose LSD pill cut depression scores by 13 points vs 5 for placebo, with effects holding at 12 weeks.
A stem cell therapy for geographic atrophy showed sustained vision gains and retinal repair three years after a single injection in a Phase 1/2a trial.
RZ-001 earns rare RMAT designation for hepatocellular carcinoma, signaling RNA editing's rise as a precise, programmable cancer treatment.
RBI's Wnt-activated stem cells injected directly into the brain show early promise reducing tau and amyloid markers in Phase 1.
Biotech company Rubedo announces preliminary positive results for RLS-1496, a drug targeting aging cells for cellular rejuvenation.
RTX001, a regenerative macrophage cell therapy, reduced liver inflammation and fibrosis in mouse models ahead of Phase I/II trial results.
Life Biosciences begins groundbreaking human trials testing cellular reprogramming therapy to reverse aging at the cellular level.
COYA 302 combines low-dose IL-2 and CTLA-4 Ig to boost regulatory T cells and curb ALS-driving inflammation, now on an expedited FDA path.
Astellas reports encouraging early-stage results for a stem cell-derived treatment targeting age-related eye disease, though data remains limited.
New research reveals 30-minute sauna sessions mobilize immune cells, mimicking exercise benefits for immune system activation.
CellProthera's ProtheraCytes targets heart repair post-myocardial infarction, aiming to prevent heart failure before damage becomes irreversible.
